Initiation of buprenorphine during incarceration and retention in treatment upon release.
Nickolas Zaller,Michelle McKenzie,Michelle McKenzie,Peter D. Friedmann,Peter D. Friedmann,Traci C. Green,Traci C. Green,Samuel K. McGowan,Josiah D. Rich,Josiah D. Rich +9 more
Reads0
Chats0
TLDR
It is concluded that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.About:
This article is published in Journal of Substance Abuse Treatment.The article was published on 2013-08-01 and is currently open access. It has received 63 citations till now. The article focuses on the topics: Buprenorphine & Naloxone.read more
Citations
More filters
Journal ArticleDOI
Prevention and Treatment of Opioid Misuse and Addiction: A Review.
TL;DR: The factors that triggered the opioids crisis and its further evolution are analyzed, along with the interventions to manage and prevent opioid use disorder (OUD), which are fundamental for curtailing the opioid crisis.
BookDOI
Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
TL;DR: Evidence on strategies for addressing the opioid epidemic and progress and future directions in research on pain and opioid use disorder are presented.
Journal ArticleDOI
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review
Monica Malta,Monica Malta,Monica Malta,Thepikaa Varatharajan,Cayley Russell,Michelle Pang,Sarah Bonato,Benedikt Fischer,Benedikt Fischer,Benedikt Fischer +9 more
TL;DR: It is found that correctional facilities should scale up OAT among incarcerated persons with OUD, and participants who received MMT or BPN/NLX while incarcerated had fewer nonfatal overdoses and lower mortality.
Journal ArticleDOI
A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry
Michael S. Gordon,Timothy W. Kinlock,Robert P. Schwartz,Terrence T. Fitzgerald,Kevin E. O'Grady,Frank Vocci +5 more
TL;DR: Buprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry, however, concerns remain with in-prison treatment termination due to attempted diversion of medication.
Journal ArticleDOI
Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont.
TL;DR: For state Medicaid leaders facing similar decisions on approaches to opioid addiction, these results provide early support for expanding medication-assisted treatment services rather than relying only on psychosocial, abstinence, or detoxification interventions.
References
More filters
Journal ArticleDOI
Interventions for latent autoimmune diabetes (LADA) in adults.
TL;DR: Two studies show SU leading to earlier insulin dependence and a meta-analysis of four studies with considerable heterogeneity showed poorer metabolic control if SU is prescribed for patients with LADA compared to insulin.
Journal ArticleDOI
The fifth edition of the addiction severity index
A. Thomas McLellan,Harvey Kushner,David S. Metzger,Roger H. Peters,Iris E. Smith,Grant R. Grissom,Helen M. Pettinati,Milton Argeriou +7 more
TL;DR: The clinical and research uses of the ASI over the past 12 years are discussed, emphasizing some special circumstances that affect its administration.
Journal ArticleDOI
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
TL;DR: Buprenorphine maintenance compared to placebo and to methadone maintenance in the management of opioid dependence, including its ability to retain people in treatment, suppress illicit drug use, reduce criminal activity, and mortality is evaluated.
Journal ArticleDOI
Release from Prison — A High Risk of Death for Former Inmates
Ingrid A. Binswanger,Marc Stern,Richard A. Deyo,Patrick J. Heagerty,Allen Cheadle,Joann G. Elmore,Thomas D. Koepsell +6 more
TL;DR: Former prison inmates were at high risk for death after release from prison, particularly during the first 2 weeks, and interventions are necessary to reduce the risk of death after released from prison.
Journal ArticleDOI
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Sharon L. Walsh,Sharon L. Walsh,Kenzie L. Preston,Kenzie L. Preston,Maxine L. Stitzer,Maxine L. Stitzer,Edward J. Cone,Edward J. Cone,George E. Bigelow,George E. Bigelow +9 more
TL;DR: The purpose of this study was to characterize the acute effects of buprenorphine, an opioid partial (μ‐agonist, across a wide range of doses in comparison to methadone.